- Home
- CDIO vs KTTA Comparison
CDIO vs KTTA Comparison
Compare CDIO & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- KTTA
- Stock Information
- Founded
- CDIO 2017
- KTTA 2020
- Country
- CDIO United States
- KTTA United States
- Employees
- CDIO N/A
- KTTA N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- CDIO Health Care
- KTTA Health Care
- Exchange
- CDIO Nasdaq
- KTTA Nasdaq
- Market Cap
- CDIO 6.4M
- KTTA 5.1M
- IPO Year
- CDIO N/A
- KTTA 2021
- Fundamental
- Price
- CDIO $3.76
- KTTA $0.79
- Analyst Decision
- CDIO
- KTTA
- Analyst Count
- CDIO 0
- KTTA 0
- Target Price
- CDIO N/A
- KTTA N/A
- AVG Volume (30 Days)
- CDIO 29.6K
- KTTA 178.0K
- Earning Date
- CDIO 08-14-2025
- KTTA 08-14-2025
- Dividend Yield
- CDIO N/A
- KTTA N/A
- EPS Growth
- CDIO N/A
- KTTA N/A
- EPS
- CDIO N/A
- KTTA N/A
- Revenue
- CDIO $19,507.00
- KTTA N/A
- Revenue This Year
- CDIO $1,434.82
- KTTA N/A
- Revenue Next Year
- CDIO $4,661.91
- KTTA N/A
- P/E Ratio
- CDIO N/A
- KTTA N/A
- Revenue Growth
- CDIO N/A
- KTTA N/A
- 52 Week Low
- CDIO $3.22
- KTTA $0.65
- 52 Week High
- CDIO $53.10
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- CDIO 47.81
- KTTA 54.58
- Support Level
- CDIO $3.62
- KTTA $0.75
- Resistance Level
- CDIO $3.99
- KTTA $0.91
- Average True Range (ATR)
- CDIO 0.27
- KTTA 0.06
- MACD
- CDIO 0.03
- KTTA 0.01
- Stochastic Oscillator
- CDIO 68.00
- KTTA 45.79
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).